Evaluating the "Leeds criteria'' for Pseudomonas aeruginosa infection in a cystic fibrosis centre

Evaluating the "Leeds criteria'' for Pseudomonas aeruginosa infection in a cystic fibrosis centre
复制标题

DOI:
10.1183/09031936.06.00100805
复制
发表时间:
2006-05-01
影响因子:
24.3
通讯作者:
de Boeck, K
de Boeck, K
中科院分区:
医学1区
文献类型:
--
作者:
Proesmans, M;Balinska-Miskiewicz, W;de Boeck, K

文献摘要

被引文献

相似文献

囊性纤维化(CF)儿童慢性铜绿假单胞菌(PA)感染的四种不同类型的定义是基于前一年的呼吸道培养。本研究的目的是用临床、免疫学和肺功能参数来评估目前作者在儿科和成人CF门诊中的定义。在193例患者中,55例(34%)从未感染过PA,27例(17%)没有感染PA,29例(18%)为间歇性感染,51例(31%)为慢性感染。疾病严重程度指标,如肺功能,在慢性病组显著恶化,特别是在儿科人群中。成年患者的差异较小,不再显著。PA抗体在不同组之间差异很大,非常高(平均+/-SD55.4+/-5.5),与慢性组中的所有其他组相比具有非常显著的统计学意义。他们较低,与从不组中的所有其他组(1.8+/-0.6)不同。铜绿假单胞菌抗体与间歇性铜绿假单胞菌抗体无差异。结论是,根据新的定义,铜绿假单胞菌的状态与临床状态以及铜绿假单胞菌抗体水平之间存在一致性。
Four separate categories of chronic Pseudomonas aeruginosa (Pa) infection in children with cystic fibrosis (CF) have been previously defined, based on airway cultures taken over the previous year.The aim of the present study was to evaluate this definition in the current authors' paediatric and adult CF clinic using clinical, immunological and lung function parameters.During follow-up, out of 193 patients, 55 (34%) CF patients had never been infected with Pa, 27 (17%) were free of Pa, 29 (18%) were intermittently infected and 51 (31%) were chronically infected. Disease severity markers, such as lung function, were significantly worse in the chronic group, especially in the paediatric population. Differences in adult patients were smaller and no longer significant. Pa antibodies differed strongly between the groups, and were very high (mean +/- SD 55.4 +/- 5.5) and highly statistically significant from all other groups in the chronic group. They were low and different from all other groups in the never group (1.8 +/- 0.6). Pa antibodies did not differ between the free of Pa and the intermittent group.In conclusion, the current authors confirmed an agreement between Pseudomonas aeruginosa status according to the new definition and clinical status, as well as with the level of Pseudomonas aeruginosa antibodies.